Leading Heart Valve Company Proposes Billion-Dollar Compensation Package to New CFO

Edwards Lifesciences Corp. (NYSE: EW), the U.S. structural heart disease device maker, has offered incoming CFO Theodora “Doretta” Mistras a comprehensive compensation package that includes a base salary of $925,000, a cash signing bonus of approximately $2.01 million, $8 million in new restricted stock units, and $4.5 million in annual equity awards beginning in 2026.

For the quarter ended March 31, the company reported revenue of $1.65 billion, up 16.7% year-over-year, driven by strong sales of its transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapy (TMTT) systems. Edwards also raised its full-year revenue growth guidance and completed about $500 million of its share repurchase program.

CEO Bernard Jobigian disclosed in a regulatory filing that, following the vesting of performance-based RSUs worth several million dollars in early May, he sold a portion of his shares under a 10b5-1 trading plan but still holds tens of millions of dollars’ worth of company stock.

In a May 4 press release, Edwards confirmed Mistras’s appointment as CFO effective at the end of May. She has already participated in key investor events, including BofA Securities’ 2026 Healthcare Conference, where she outlined the company’s structural heart disease portfolio and growth strategy.

Headquartered in Irvine, California, Edwards Lifesciences specializes in devices for structural heart disease. Its flagship products include the minimally invasive TAVR system for treating aortic stenosis, catheter-based mitral and tricuspid repair devices, and critical care and surgical monitoring solutions, all poised to benefit from aging populations and rising cardiovascular disease incidence.